Figure 1 |
Common Treatments of Cancer |
Figure 2 |
Global Metastatic Cancer Treatment Market ($Million) |
Figure 3 |
Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2017 |
Figure 4 |
Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2025 |
Figure 5 |
Global Metastatic Cancer Treatment Market by Products, 2017 |
Figure 6 |
Global Metastatic Cancer Treatment Market By Products, 2025 |
Figure 7 |
Global Metastatic Cancer Treatment Market by Region, 2017 |
Figure 8 |
Global Injectable Drug Delivery Market by Region, 2025 |
Figure 1.1 |
Causes of Cancer |
Figure 1.2 |
Common Mechanism of Metastasis |
Figure 1.3 |
Types of Metastatic Cancer (based on how far it has spread) |
Figure 1.4 |
Global Metastatic Cancer Treatment Market, 2016-2025 ($ Million) |
Figure 2.1 |
Market Dynamics: Drivers, Restraints & Opportunities |
Figure 2.2 |
Targeted Therapies Designed for Different Cancer Types |
Figure 3.1 |
Industry Insights (January 2014-February 2018) |
Figure 4.1 |
Competitive Landscape (January 2014-February 2018) |
Figure 4.2 |
Share of Key Developments and Strategies(January 2014 to March 2018) |
Figure 4.3 |
Product Approvals by Companies |
Figure 4.4 |
Clinical Study, by Companies |
Figure 4.5 |
Product Approvals by Companies |
Figure 4.6 |
Porter’s Five Forces Analysis |
Figure 5.1 |
Types of Metastatic Cancer by Therapeutic Indication |
Figure 5.2 |
Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2014-2025 ($Million) |
Figure 5.3 |
Signs and Symptoms of Metastatic Breast Cancer |
Figure 5.4 |
Common Molecular Subtypes of Breast Cancer |
Figure 5.5 |
Global Metastatic Cancer Treatment Market by Breast Cancer, 2014-2025 ($ Million) |
Figure 5.6 |
List of Common Metastatic Breast Cancer Drugs |
Figure 5.7 |
Signs and Symptoms of Metastatic Melanoma |
Figure 5.8 |
Global Metastatic Cancer Treatment Market by Melanoma Cancer, 2014-2025 ($ Million) |
Figure 5.9 |
List of Common Metastatic Melanoma Cancer Drugs |
Figure 5.10 |
Signs and Symptoms of Metastatic Prostate Cancer |
Figure 5.11 |
Global Metastatic Cancer Treatment Market by Prostate Cancer, 2014-2025 ($ Million) |
Figure 5.12 |
List of Common Metastatic Prostate Cancer Drugs |
Figure 5.13 |
Signs and Symptoms of Metastatic Lung Cancer |
Figure 5.14 |
Global Metastatic Cancer Treatment Market by NSCLC, 2014-2025 ($ Million) |
Figure 5.15 |
List of Common Metastatic Lung Cancer Drugs |
Figure 5.16 |
Signs and Symptoms of Metastatic Colorectal Cancer |
Figure 5.17 |
Global Metastatic Cancer Treatment Market by Colorectal Cancer, 2014-2025 ($ Million) |
Figure 5.18 |
List of Common Metastatic Colorectal Cancer Drugs |
Figure 5.19 |
Global Metastatic Cancer Treatment Market by Other Cancers, 2014-2025 ($ Million) |
Figure 6.1 |
Classification of Anti-Cancer Drugs by Pharma Class |
Figure 6.2 |
Global Metastatic Cancer Treatment Market by Branded Medicines, 2014-2025 ($ Million) |
Figure 6.3 |
Global Metastatic Cancer Treatment Market by Generic Medicines, 2014-2025 ($ Million) |
Figure 7.1 |
Global Metastatic Cancer Treatment Market by Region, 2014-2025 ($Million) |
Figure 7.2 |
North America Metastatic Cancer Treatment Market, 2014-2025 ($Million) |
Figure 7.3 |
North America Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million) |
Figure 7.4 |
Cancer Patient Data by Cancers Type in the U.S. (2016) |
Figure 7.5 |
Cancer Patient Data by Cancers Type in Canada (2016) |
Figure 7.6 |
The U.S. Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.7 |
Canada Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.8 |
Europe Metastatic Cancer Treatment Market, 2014-2025 ($Million) |
Figure 7.9 |
Europe Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million) |
Figure 7.10 |
Cancer Patient Data by Cancers Type in Germany (2016) |
Figure 7.11 |
Cancer Patient Data by Cancers Type in France (2016) |
Figure 7.12 |
Cancer Patient Data by Cancers Type in Italy (2016) |
Figure 7.13 |
France Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.14 |
Germany Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.15 |
Italy Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.16 |
Netherland Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.17 |
Switzerland Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.18 |
The U.K. Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.19 |
Spain Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.20 |
Sweden Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.21 |
Austria Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.22 |
Belgium Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.23 |
Denmark Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.24 |
Finland Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.25 |
Poland Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.26 |
Russia Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.27 |
Ireland Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.28 |
Rest of Europe Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.29 |
Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($Million) |
Figure 7.30 |
Asia Pacific Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million) |
Figure 7.31 |
Cancer Patient Data by Cancers Type in China (2016) |
Figure 7.32 |
Cancer Patient Data by Cancers Type in Japan (2016) |
Figure 7.33 |
Cancer Patient Data by Cancers Type in India (2016) |
Figure 7.35 |
China Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.36 |
Japan Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.37 |
India Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.38 |
South Korea Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.39 |
Australia Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.40 |
Bangladesh Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.41 |
Malaysia Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.42 |
New Zealand Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.43 |
Rest of Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.44 |
Latin America Metastatic Cancer Treatment Market, 2014-2025 ($Million) |
Figure 7.45 |
Latin America Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million) |
Figure 7.46 |
Brazil Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.47 |
Mexico Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.48 |
Argentina Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.49 |
Rest of Latin America Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.50 |
Rest of the World (RoW) Metastatic Cancer Treatment Market, 2014-2025 ($Million) |
Figure 7.51 |
Rest of the World (RoW) Metastatic Cancer Treatment Market by Country, 2014-2025 ($Million) |
Figure 7.52 |
Saudi Arabia Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.53 |
UAE Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.54 |
South Africa Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.55 |
Israel Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 7.56 |
Other Metastatic Cancer Treatment Market, 2014-2025 ($million) |
Figure 8.1 |
Contribution of Various companies |
Figure 8.2 |
AbbVie Inc.: Overall Product Portfolio |
Figure 8.3 |
AbbVie Inc.: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.4 |
AbbVie Inc.: Overall Financials (2014-2017) |
Figure 8.5 |
AbbVie Inc.: Revenue by Geography (2014-2017) |
Figure 8.6 |
AbbVie Inc.: Global Presence |
Figure 8.7 |
AbbVie Inc.: SWOT Analysis |
Figure 8.8 |
Amgen, Inc.: Overall Product Portfolio |
Figure 8.9 |
Amgen, Inc.: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.10 |
Amgen, Inc. : Overall Financials (2014-2017) |
Figure 8.11 |
Amgen, Inc. : Revenue by Geography (2014-2017) |
Figure 8.12 |
Amgen, Inc.: Global Presence |
Figure 8.13 |
Amgen, Inc. : SWOT Analysis |
Figure 8.14 |
AstraZeneca PLC: Overall Product Portfolio |
Figure 8.15 |
AstraZeneca PLC: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.16 |
AstraZeneca PLC: Overall Financials (2014-2017) |
Figure 8.17 |
AstraZeneca PLC: Revenue by Product Sales (2014-2017) |
Figure 8.18 |
AstraZeneca PLC: Revenue by Geography (2014-2017) |
Figure 8.19 |
AstraZeneca PLC: Global Presence |
Figure 8.20 |
AstraZeneca PLC: SWOT Analysis |
Figure 8.21 |
Bayer AG: Overall Product Portfolio |
Figure 8.22 |
Bayer AG: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.23 |
Bayer AG: Overall Financials (2014-2017) |
Figure 8.24 |
Bayer AG: Revenue by Geography (2014-2017) |
Figure 8.25 |
Bayer AG: Revenue by Business Segment (2014-2015) |
Figure 8.26 |
Bayer AG: Revenue by Buisness Segment (2016-2017) |
Figure 8.27 |
Bayer AG: Global Presence |
Figure 8.28 |
Bayer AG: SWOT Analysis |
Figure 8.29 |
Boehringer Ingelheim International GmbH: Overall Product Portfolio |
Figure 8.30 |
Boehringer Ingelheim International GmbH: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.31 |
Boehringer Ingelheim International GmbH: Overall Financials (2014-2017) |
Figure 8.32 |
Boehringer Ingelheim International GmbH: Revenue by Geography (2014-2017) |
Figure 8.33 |
Boehringer Ingelheim International GmbH: Revenue by Business Segment (2014-2015) |
Figure 8.34 |
Boehringer Ingelheim International GmbH: Revenue by Buisness Segment (2016-2017) |
Figure 8.35 |
Boehringer Ingelheim International GmbH: Global Presence |
Figure 8.36 |
Boehringer Ingelheim International GmbH: SWOT Analysis |
Figure 8.37 |
BRISTOL-MYERS SQUIBB COMPANY: Overall Product Portfolio |
Figure 8.38 |
BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.39 |
BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2017) |
Figure 8.40 |
BRISTOL-MYERS SQUIBB COMPANY: Revenue by Geography (2014-2017) |
Figure 8.41 |
BRISTOL-MYERS SQUIBB COMPANY: Global Presence |
Figure 8.42 |
BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis |
Figure 8.43 |
CELGENE CORPORATION: Overall Product Portfolio |
Figure 8.44 |
CELGENE CORPORATION: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.45 |
CELGENE CORPORATION: Overall Financials (2014-2017) |
Figure 8.46 |
CELGENE CORPORATION: Revenue by Geography (2014-2017) |
Figure 8.47 |
CELGENE CORPORATION: Global Presence |
Figure 8.48 |
CELGENE CORPORATION: SWOT Analysis |
Figure 8.49 |
Eli-Lilly and Company: Overall Product Portfolio |
Figure 8.50 |
Eli-Lilly and Company: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.51 |
Eli-Lilly and Company: Overall Financials (2014-2017) |
Figure 8.52 |
Eli-Lilly and Company: Revenue by Business segment (2014-2017) |
Figure 8.53 |
Eli-Lilly and Company: Revenue by Geography (2014-2017) |
Figure 8.54 |
Eli-Lilly and Company: Global Presence |
Figure 8.55 |
Eli-Lilly and Company: SWOT Analysis |
Figure 8.56 |
F. Hoffmann-La Roche AG: Overall Product Portfolio |
Figure 8.57 |
F. Hoffmann-La Roche AG: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.58 |
F. Hoffmann-La Roche AG: Overall Financials (2014-2017) |
Figure 8.59 |
F. Hoffmann-La Roche AG: Product Sales by Region (2014-2017) |
Figure 8.60 |
F. Hoffmann-La Roche AG: Revenue by Division (2014-2017) |
Figure 8.61 |
F. Hoffmann-La Roche AG: Revenue by Pharmaceutical Sub-Segment (2014-2017) |
Figure 8.62 |
F. Hoffmann-La Roche AG: Global Presence |
Figure 8.63 |
F. Hoffmann-La Roche AG: SWOT Analysis |
Figure 8.64 |
JOHNSON & JOHNSON: Overall Product Portfolio |
Figure 8.65 |
JOHNSON & JOHNSON: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.66 |
JOHNSON & JOHNSON: Overall Financials (2014-2017) |
Figure 8.67 |
JOHNSON & JOHNSON: Revenue by Business segment (2014-2017) |
Figure 8.68 |
JOHNSON & JOHNSON: Revenue by Geography (2014-2017) |
Figure 8.69 |
JOHNSON & JOHNSON: Global Presence |
Figure 8.70 |
JOHNSON & JOHNSON: SWOT Analysis |
Figure 8.71 |
Merck & Co., Inc.: Overall Product Portfolio |
Figure 8.72 |
Merck & Co., Inc.: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.73 |
Merck & Co., Inc.: Overall Financials (2014-2017) |
Figure 8.74 |
Merck & Co., Inc.: Revenue by Business segment (2014-2017) |
Figure 8.75 |
Merck & Co., Inc.: Revenue by Geography (2014-2017) |
Figure 8.76 |
Merck & Co., Inc.: Global Presence |
Figure 8.77 |
Merck & Co., Inc.: SWOT Analysis |
Figure 8.78 |
Novartis AG: Overall Product Portfolio |
Figure 8.79 |
Novartis AG: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.80 |
Novartis AG: Overall Financials (2014-2017) |
Figure 8.81 |
Novartis AG: Revenue by Geography (2014-2017) |
Figure 8.82 |
Novartis AG: Revenue by Business Segment (2014-2015) |
Figure 8.83 |
Novartis AG: Revenue by Buisness Segment (2016-2017) |
Figure 8.84 |
Novartis AG: Global Presence |
Figure 8.85 |
Novartis AG: SWOT Analysis |
Figure 8.86 |
Pfizer, Inc.: Overall Product Portfolio |
Figure 8.87 |
Pfizer, Inc.: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.88 |
Pfizer, Inc.: Overall Financials (2014-2017) |
Figure 8.89 |
Pfizer, Inc.: Revenue by Business segment (2014-2017) |
Figure 8.90 |
Pfizer, Inc.: Revenue by Geography (2014-2017) |
Figure 8.91 |
Pfizer, Inc.: Global Presence |
Figure 8.92 |
Pfizer, Inc.: SWOT Analysis |
Figure 8.93 |
SANOFI: Overall Product Portfolio |
Figure 8.94 |
SANOFI: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.95 |
SANOFI: Overall Financials (2014-2017) |
Figure 8.96 |
SANOFI: Revenue by Business Segment (2014-2015) |
Figure 8.97 |
SANOFI: Revenue by Business Segment (2016-2017) |
Figure 8.98 |
SANOFI: Revenue by Geography (2014-2015) |
Figure 8.99 |
SANOFI: Revenue by Geography (2016-2017) |
Figure 8.100 |
SANOFI: Global Presence |
Figure 8.101 |
SANOFI: SWOT Analysis |
Figure 8.102 |
Takeda Pharmaceutical Company Limited: Overall Product Portfolio |
Figure 8.103 |
Takeda Pharmaceutical Company Limited: Product Portfolio for Metastatic Cancer Treatment Market |
Figure 8.104 |
Takeda Pharmaceutical Company Limited: Overall Financials (2014-2017) |
Figure 8.105 |
Takeda Pharmaceutical Company Limited: Revenue by Business segment (2014-2017) |
Figure 8.106 |
Takeda Pharmaceutical Company Limited: Revenue by Geography (2014-2017) |
Figure 8.107 |
Takeda Pharmaceutical Company Limited: Global Presence |
Figure 8.108 |
Takeda Pharmaceutical Company Limited: SWOT Analysis |
Figure 8.109 |
bluebird bio, Inc.: Product Pipeline for Cancer Treatment Market |
Figure 8.110 |
Clovis Oncology, Inc.: Product Pipeline for Cancer Treatment Market |
Figure 8.111 |
IDERA PHARMACEUTICALS, INC.: Product Pipeline for Cancer Treatment Market |
Figure 8.112 |
eTheRNA immunotherapies NV: Product Pipeline for Cancer Treatment Market |
Figure 9.1 |
Global Metastatic Cancer Treatment Market Segmentation |
Figure 9.2 |
Considered Factors for Data Prediction & Modeling |